Study of a targeted radioactive drug for αVβ3-positive tumors
Part of Cancer clinical trials.
This early-phase study tests whether a targeted radioactive medicine (177Lu-AB-3PRGD2) can shrink or control tumors that strongly match a specific target seen on special scans. It may help people whose current standard treatments are not working or are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed cancer diagnosis, and standard treatment is not working or is progressing
- Your tumor must show high RGD signal on a 68Ga-RGD PET/CT scan within about 1 week before treatment
- You can sign informed consent (agree to join the study after understanding it)
- Your blood counts and liver/kidney lab tests must be high enough to safely receive treatment
- You must not have major heart failure, serious contrast allergy, severe claustrophobia, or other issues that would prevent following the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (177Lu-TATE-RGD) that targets two specific markers on tumor cells. It is for people whose cancer has not responded to standard treatments and whose tumors show high levels of these markers on a PET scan.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Hear when a new Integrin αVβ3 Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.